News
GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.
GoodRx (Nasdaq: GDRX) has teamed up with Novo Nordisk (NOV: N) to make all dose levels of Ozempic (semaglutide) and Wegovy ...
GoodRx stock soars after announcing GLP-1 partnership with Novo Nordisk. A Bank of America analyst recommends selling GDRX ...
Interestingly, Wall Street firms largely believe the former will playout in the long run. According to The Wall Street ...
1d
StockStory.org on MSNWhy GoodRx (GDRX) Stock Is Trading Up Today
Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 40.2% in the afternoon session after the company announced a ...
GoodRx shares are pulling back Tuesday morning. The stock had jumped over 30% Monday after the company announced a new ...
GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that via a collaboration with ...
Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...
GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing. Click ...
We recently published 12 Best Healthcare Stocks to Buy Under $30. GoodRx Holdings, Inc. (NASDAQ:GDRX) is one of the best ...
2d
TipRanks on MSNGoodRx enters pact with Novo Nordisk to expand Ozempic, Wegovy access
GoodRx (GDRX) announced that via a collaboration with Novo Nordisk (NVO), all strengths of Ozempic and Wegovy pens are available to eligible ...
GoodRx's Q2 expected to be in line with guidance, but long-term guidance doesn't support current price point. See why I maintain my sell rating on GDRX stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results